Agenda for Day 1– Wednesday December 9, 2026Wednesday, 9 December 2026 - US/Eastern

Compounding Pharmacies continue to face evolving regulatory scrutiny, increasing operational complexity, and shifting market opportunities. This opening session will provide a comprehensive overview of the developments most likely to impact pharmacy operations, compliance programs, and growth strategies heading into 2027.

Discussion Topics

• FDA enforcement trends and inspection activity

• State board developments and regulatory priorities

• USP implementation considerations

• Ongoing market shifts following GLP-1 demand growth

• Emerging business and compliance risks

As compounding pharmacies pursue new growth opportunities, they are increasingly evaluating partnerships with telehealth organizations, med spas, and other pharmacies. This panel examines how to structure these relationships while navigating regulatory expectations, contractual obligations, and operational responsibilities.

Discussion Topics

• Structuring compliant 503A–503B business relationships
• Telehealth partnerships, referral models, and vertical integration
• Working with med spas while maintaining compliance
• Contracting, governance, and allocation of compliance responsibilities
• Patient-specific prescription and fulfillment considerations within partnership models
• Due diligence, documentation, and risk management
• Recent enforcement activity and lessons learned

Join pharmacy regulators for a candid discussion on inspection trends, enforcement priorities, and the compliance issues receiving the greatest attention from state boards.

Discussion Topics

• Common inspection findings

• Enforcement priorities

• Telehealth-related concerns

• Nonresident pharmacy oversight

• Preparing for successful inspections

As pharmacies continue expanding nationally, regulatory requirements continue to diverge. This session examines how organizations are operationalizing compliance across multiple jurisdictions.

Discussion Topics

• State licensing requirements

• Shipping restrictions

• Inspection expectations

• Telehealth-related regulations

• Building scalable compliance systems

Even well-prepared compounding facilities can face unanticipated challenges during regulatory inspections. In this candid case study, Jack Korbutov, Founder & President of The Art of Medicine Compounding Facility, will share his experience with a unique DEA disciplinary action and the critical lessons learned that can help others safeguard their operations before similar issues arise.

Discussion Topics

• Overview of the DEA inspection and disciplinary action

• Compliance vulnerabilities that standard preparation may not address

• Unexpected findings and regulatory interpretation challenges

• Actionable strategies to strengthen DEA readiness

• Best practices for navigating inspections and protecting your license

Compounded peptides, GLP-1 products, and other emerging therapies continue to reshape the compounding landscape amid evolving FDA oversight and heightened regulatory scrutiny. This session provides a year-end update on the most significant legal, regulatory, and market developments, including the implications of the FDA’s July peptide review and what they mean for pharmacies moving forward.

Discussion Topics

• Key takeaways from the FDA’s July review of 14 commonly compounded peptides

• Implications for therapies such as BPC-157, Thymosin Alpha-1, and TB-500

• FDA enforcement priorities and recent regulatory developments

• GLP-1 enforcement, marketing, and advertising considerations

• Litigation updates and emerging peptide regulations

• How pharmacies and prescribers are adapting to the evolving regulatory landscape

• Compliance strategies to mitigate regulatory risk

• Looking ahead: the future of compounded peptides and other emerging therapies

Explore the next generation of compliance through AI and data integration. 

• Learn how automation reduces human error in weighing, mixing, and batch verification. 

• Discover digital quality systems that simplify documentation and real-time monitoring. 

• Discuss regulatory considerations for AI-assisted compounding tools. 

For pharmacies considering outsourcing facility registration, understanding the operational, financial, and regulatory realities is critical.

Discussion Topics

• Capital investment requirements

• Quality system expectations

• cGMP readiness

• Regulatory obligations

• Lessons learned from successful transitions

Hear directly from Alliance for Pharmacy Compounding leadership on the most important regulatory, legislative, and advocacy developments impacting pharmacies nationwide.

Discussion Topics

• Federal and state legislative priorities

• Ongoing FDA engagement efforts

• GLP-1 and peptide developments

• Industry advocacy initiatives

• Key issues expected to shape 2027